164 related articles for article (PubMed ID: 28641632)
21. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
Khaled HM; Zekri ZK; Mokhtar N; Ali NM; Darwish T; Elattar I; Gaafar R; Moawad MS
Ann Oncol; 1999 Dec; 10(12):1489-92. PubMed ID: 10643541
[TBL] [Abstract][Full Text] [Related]
22. R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T; Yoshikawa T; Goto H; Sawada M; Yamada T; Fukuno K; Kasahara S; Shibata Y; Matsumoto T; Mabuchi R; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Nannya Y; Katsumura N; Takahashi T; Kito Y; Takami T; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2018 Oct; 36(4):638-644. PubMed ID: 29882279
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
24. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
26. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
27. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Wilson WH; Grossbard ML; Pittaluga S; Cole D; Pearson D; Drbohlav N; Steinberg SM; Little RF; Janik J; Gutierrez M; Raffeld M; Staudt L; Cheson BD; Longo DL; Harris N; Jaffe ES; Chabner BA; Wittes R; Balis F
Blood; 2002 Apr; 99(8):2685-93. PubMed ID: 11929754
[TBL] [Abstract][Full Text] [Related]
28. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
[TBL] [Abstract][Full Text] [Related]
29. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
[TBL] [Abstract][Full Text] [Related]
30. [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
Schneider T; Molnár Z; Deák B; Várady E; Tóth E; Csomor J; Matolcsy A; Lovey J; Lengyel Z; Petri K; Gaudi I; Rosta A
Orv Hetil; 2009 Nov; 150(44):2019-26. PubMed ID: 19861288
[TBL] [Abstract][Full Text] [Related]
31. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
32. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
34. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
Morgenstern Y; Aumann S; Goldschmidt N; Gatt ME; Nachmias B; Horowitz NA
Cancer Med; 2021 Dec; 10(24):8866-8875. PubMed ID: 34816617
[TBL] [Abstract][Full Text] [Related]
35. Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Mitrovic Z; Dujmovic D; Jaksic O; Kinda SB; Gacina P; Perisa V; Prka Z; Dreta B; Galusic D; Holik H; Pejsa V; Aurer I
Eur J Haematol; 2023 Jun; 110(6):725-731. PubMed ID: 36941738
[TBL] [Abstract][Full Text] [Related]
36. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
37. Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma.
García-Suárez J; Flores E; Callejas M; Arribas I; Gil-Fernández JJ; Olmedilla G; Curto N; Guillén H; Casco CR; Martín Y; Burgaleta C
Br J Haematol; 2013 Feb; 160(4):510-4. PubMed ID: 23228045
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
39. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
Cancer; 2015 Jun; 121(11):1800-8. PubMed ID: 25675909
[TBL] [Abstract][Full Text] [Related]
40. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
